Intranasal Dexmedetomidine Versus Oral Midazolam as Premedication for Propofol Sedation in Pediatric Patients Undergoing Magnetic Resonance Imaging
MRI, Pediatric Sedation, Midazolam

About this trial
This is an interventional treatment trial for MRI
Eligibility Criteria
Inclusion Criteria:
- Children of both sexes, aged 6 months to 6 years,
- ASA score I to IV,
- Requiring standard magnetic resonance imaging due to clinical condition, regardless of underlying pathology,
- Sedation performed by an anesthesiologist,
- Written informed consent in accordance with the ICH-GCP and local legislation prior to trial entry.
Exclusion Criteria:
- Contraindications to MRI (cardiac pacemaker, neurostimulator, ferromagnetic implant),
- Sedation carried out by a non-anesthesiologist,
- Emergency MRI,
- Presence of head trauma,
- Presence of nasal congestion or upper respiratory tract infection on the day of sedation,
- Multiple procedures during the same sedation (operating room, evoked potentials, etc.),
- Children with pathologies requiring airway safety,
- Any known allergic or hypersensitivity reaction to dexmedetomidine,
- Any known allergic or hypersensitivity reaction to benzodiazepines,
- Concomitant use of negative chronotropes, as Digoxine,
- Patient known with chronic respiratory failure or myasthenia,
- Patient known with anatomical abnormality of the airway, lung disease or sleep apnea syndrome
- Patient with known cardiac rhythm abnormality or cardio-vascular disease,
- Patient with known hepatic disorder or chronic kidney disease,
- Patient with hypotension or bradycardia on the day of the examination,
- Patient with a BMI > 97th percentile (which corresponds to overweight, including obesity).
Sites / Locations
- Hôpital Universitaire des Enfants Reine FabiolaRecruiting
Arms of the Study
Arm 1
Arm 2
Active Comparator
Experimental
Group Midazolam
Group Dexmedetomidine
Administration of oral midazolam (0.25 mg/kg) as premedication before propofol-based sedation. The patient receives an oral premedication containing 0.125mL/kg of midazolam (which corresponds to a dosage of 0.25mg/kg of Ozalin® 2mg/ml, with a maximum of 20 mg). He/she also receives an intranasal spray containing matching placebo of dexmedetomidine (NaCl 0.9%). The volume administered corresponds to 0.02 mL/kg (which corresponds to a dosage of 2 mcg/kg of pure dexmedetomidine 100 mcg/mL in group D).
Administration of intranasal dexmedetomidine as premedication before propofol-based sedation. The patient receives an intranasal premedication containing 2 mcg/kg of dexmedetomidine. He/she also receives an oral solution containing matching placebo of midazolam (flavored-water prepared by the pharmacy). The volume administered corresponds to 0.125 mL/kg (which corresponds to a dosage of 0.25mg/kg of Ozalin® 2mg/mL, with a maximum of 20 mg or 10mL).